Recurrent Non-Hodgkin's Lymphoma


CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

What’s New in the Management of Lymphoma? (March 2, 2015)

What’s New in the Management of Lymphoma? Cancers that begin in cells of the lymph system are referred to as malignant lymphomas. Lymphomas range from aggressive to slow growing or indolent and can be... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

CancerConnect News: HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised... Continue Reading

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL (September 4, 2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma... Continue Reading

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI) (September 3, 2014)

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™)... Continue Reading

Pidilizumab Plus Rituxan Produces High Response Rate in Relapsed Follicular Lymphoma (January 10, 2014)

Treatment with the monoclonal antibody pidilizumab plus Rituxan® (rituximab) produced a high response rate in patients with relapsed follicular lymphoma, according to the results of a study published... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published... Continue Reading

Adcetris Approved for Two Types of Lymphoma (August 26, 2011)

The targeted therapy Adcetris™ (brentuximab vedotin) has received accelerated approved by the US Food and Drug Administration (FDA) for the treatment of two types of lymphoma: Hodgkin lymphoma and systemic... Continue Reading

Brentuximab Vedotin Effective for Patients with Relapsed or Refractory Anaplastic Large Cell Lymphoma (June 16, 2011)

Researchers involved in an international multicenter trial have reported that brentuximab vedotin was effective for treatment of patients with relapsed or refractory anaplastic large cell lymphoma. The... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients.... Continue Reading

Survivors of Some Childhood Cancers May Face Cognitive Impairment (May 18, 2010)

Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according... Continue Reading

Children and Teens Have Better NHL Survival than Young Adults (March 15, 2010)

Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in... Continue Reading

Cancer Caregivers Devote Substantial Time and Effort (September 9, 2009)

On average, informal caregivers of cancer patients devote more than eight hours per day to caregiving. These results were published in Cancer. Informal caregiving is an important part of cancer management.... Continue Reading

September Is National Leukemia and Lymphoma Awareness Month (August 28, 2009)

As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment... Continue Reading

Management of Recurrent Intermediate NHL (August 7, 2009)

Dr. John Hainsworth of the Sarah Cannon Research Institute discusses the treatment of recurrent intermediate NHL. Q: Welcome to Understanding Cancer.  Today we are speaking with Dr. John Hainsworth, director... Continue Reading

Understanding Non-Hodgkin’s Lymphoma (August 7, 2009)

Dr. John Hainsworth of the Sarah Cannon Research Institute explains the different types of non-Hodgkin’s lymphoma. Q: Welcome to Understanding Cancer.  Today we are speaking with Dr. John Hainsworth,... Continue Reading

Veltuzumab Effective for Refractory Non-Hodgkin’s Lymphoma (July 28, 2009)

Veltuzumab is safe and effective for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma, according to the results of a study published in the Journal of Clinical Oncology.[1] Non-Hodgkin’s... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS